Invex raises $632K in first tranche of US$6.47M Rekover deal
What's the deal? Invex TherapeuticsDealroom has a profile for this one. Try Dealroom → has raised US$582.4K (roughly $632,000) in a post-IPO equity placement, issuing 11,250,000 shares at US$0.05 each to sophisticated and professional investors. The Perth-based biopharmaceutical firm completed the issue on October 30, 2026.
What does Invex do? It repurposes the approved drug Exenatide, trademarked as Presendin, to treat neurological conditions linked to elevated intracranial pressure, including acute stroke and traumatic brain injury.
Why now? The placement is the first tranche of a broader US$6.47M raise tied to Invex's proposed all-share acquisition of New Zealand biotech Rekover TherapeuticsDealroom has a profile for this one. Try Dealroom →. A further US$5.89M placement remains subject to shareholder approval.
What's the endgame? The Rekover deal would add a planned Phase 2a REVIVE study of nalfurafine for demyelinating disease, including multiple sclerosis, to Invex's existing Exenatide programs. Almost half of the wider raise is reportedly backed by Andrew Forrest's TenmileDealroom has a profile for this one. Try Dealroom →.
What could go wrong? The larger raise and the acquisition remain conditional. The expanded pipeline will need clinical progress to justify the added dilution for shareholders.
The signal: This small tranche matters less as a standalone financing than as the opening move in a strategic expansion. For a repurposing-focused biotech, bolting on a new clinical-stage asset signals an attempt to broaden its neurology footprint beyond a single approved drug.
Read more: kalkinemedia.com
Image credit: mathrock
